NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Dr. Eric Leire to join CEO Birger Jan Olsen on its Board of Directors.
Dr. Leire has currently been the CEO of DanDrit Biotech (OTCQB:DDRT) which is developing a dendritic cell-based immunotherapy for the treatment of advanced colorectal cancer (Phase III clinical trials). He also serves on the Board of Novicol International Holding Inc., a Canadian company with a microbicide commercially available in China.
Dr. Leire brings to Blake Insomnia Therapeutics a valued combination of medical professionalism with business acumen spanning over 30 years encompassing:
- Biotech - held executive positions with Paringenix, APT Therapeutics, and Biostrategies Group;
- Pharmaceutical - served in senior management at Pfizer, Boots Pharma, Schering Plough Pharmacia;
- Private Equity - partner at Biofund Venture and Medwell Capital;
- Non-Profit - HIV/AIDS Project Manager with Doctors of the World, establishing educational programs and coordinating with United Nations organization such as UNHCR, UNAIDS, UNICEF and UNDP; and
- Academia - Research Associate at the Harvard University AIDS Institute.
Dr. Eric Leire earned his MD from Grenoble University Medical School in Grenoble, France, and also holds an MBA with a Finance specialization from Institute Superieure des Affaires in Paris, France and a MBA with a Health Care Management specialization from the Kellogg Graduate School of Management, Northwestern University in Chicago, IL.
“We are very happy Dr. Leire has accepted an appointment to our Board of Directors,” said Birger Jan Olsen, President and CEO of Blake Insomnia Therapeutics. “Dr. Leire is a highly accomplished doctor and executive with an international mindset and a demonstrated ability to creatively produce tangible results in the pharmaceutical and biotech industries. We are fully assured he has the qualifications and range of experience to advance the company to the position of being the premier quality of life provider though sleep enhancement.”
Dr. Leire’s experience in the biotech industry, brings strong merit and expertise to Blake Insomnia’s future plans to engage drug regulatory agencies and conduct clinical trials. It is important to note that the Biotech industry possess the most stringent regulatory procedures that need to be fulfilled in order to achieve market approval. Given the strategic position of ZLX-1 compound and the large unmet clinical need for insomnia sufferers, Dr. Leire welcomes the opportunity to improve patient access to much needed treatment and will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance.
Blake Insomnia Therapeutics Inc.
Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™. Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.
Contact: Birger Jan Olsen, CEO Blake Insomnia Therapeutics Inc. 1(888) 612-2905 news@blakeinsomnia.com
